Novonesis Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Ester Baiget

Amministratore delegato

€3.9m

Compenso totale

Percentuale dello stipendio del CEO	33.3%
Mandato del CEO	4.8yrs
Proprietà del CEO	n/a
Durata media del management	3.6yrs
Durata media del Consiglio di amministrazione	4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ester Baiget rispetto agli utili di Novonesis?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	€283m
Mar 31 2024	n/a	n/a	€332m
Dec 31 2023	€4m	€1m	€406m
Sep 30 2023	n/a	n/a	€430m
Jun 30 2023	n/a	n/a	€460m
Mar 31 2023	n/a	n/a	€487m
Dec 31 2022	€3m	€1m	€494m
Sep 30 2022	n/a	n/a	€460m
Jun 30 2022	n/a	n/a	€418m
Mar 31 2022	n/a	n/a	€416m
Dec 31 2021	€3m	€1m	€423m
Sep 30 2021	n/a	n/a	€427m
Jun 30 2021	n/a	n/a	€409m
Mar 31 2021	n/a	n/a	€389m
Dec 31 2020	€3m	€927k	€380m

Compensazione vs Mercato: La retribuzione totale di Ester ($USD 4.11M ) è circa la media per le aziende di dimensioni simili nel mercato Austrian ($USD 4.29M ).

Compensazione vs guadagni: La retribuzione di Ester è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Ester Baiget (53 yo)

4.8yrs

Mandato

€3,903,958

Compensazione

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ester Baiget	President & CEO	4.8yrs	€3.90m	Nessun dato
Rainer Lehmann	Executive VP & CFO	less than a year	€858.60k	Nessun dato
Anders Lund	Chief Operating Officer	less than a year	€1.03m	Nessun dato
Claus Fuglsang	Chief Scientific Officer	4.2yrs	Nessun dato	Nessun dato
Tobias Bjorklund	Head of Investor Relations	no data	Nessun dato	Nessun dato
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	Nessun dato	Nessun dato
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.6yrs	Nessun dato	Nessun dato
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.8yrs	€1.02m	Nessun dato
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.6yrs	Nessun dato	Nessun dato
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	Nessun dato	Nessun dato
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	Nessun dato	Nessun dato
Peter Rosholm	Chief Executive Officer of Albumedix	8.8yrs	Nessun dato	Nessun dato

3.6yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di NZYM è considerato esperto (durata media dell'incarico 3.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jesper Brandgaard	Vice Chair of the Board	less than a year	Nessun dato	Nessun dato
Cornelis de Jong	Independent Chairman	4.8yrs	€239.07k	0.0011% € 262.4k
Kim Stratton	Independent Director	7.8yrs	€173.33k	Nessun dato
Kasim Kutay	Director	7.8yrs	€107.73k	0.00023% € 55.9k
Heine Dalsgaard	Director	4.8yrs	€143.55k	0.00065% € 157.9k
Lise Kaae	Director	less than a year	Nessun dato	Nessun dato
Lena Holskov	Employee Representative Director	11.8yrs	€66.91k	Nessun dato
Anders Knudsen	Employee Representative Director	11.8yrs	€71.77k	Nessun dato
Sharon James	Independent Director	4.8yrs	€143.55k	Nessun dato
Preben Nielsen	Employee Representative Director	3.7yrs	€107.73k	0.000090% € 21.9k
Jens Obro	Employee Representative Director	3.7yrs	€71.77k	0.00012% € 29.2k
Morten Otto Sommer	Independent Director	2.7yrs	€137.51k	0.00022% € 53.5k

4.8yrs

Durata media

58.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NZYM sono considerati esperti (durata media dell'incarico 4.8 anni).

Novonesis Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Novonesis A/S Announces Board Changes

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

New minor risk - Share price stability

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: kr.2.19 (vs kr.2.92 in 2Q 2022)

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.7% yield

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

New 90-day high: €51.50

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million